Table 1

Baseline patient characteristics shown for 1) all patients and 2) three subsets of patients within both the intervention and the control group who met specific criteria for baseline elevated A1C, LDL cholesterol, or SBP

InterventionControlP value (all patients)
All patients (n = 1,220)A1C ≥8% (64 mmol/mol) (n = 569)LDL cholesterol ≥100 mg/dL (n = 348)SBP >140/90 mmHg (n = 388)All patients (n = 1,158)A1C ≥8% 64 mmol/mol (n = 533)LDL cholesterol ≥100 mg/dL (n = 315)SBP ≥140/90 mmHg (n = 403)
Site, n (%)
 Site A161 (13.2)52 (9.1)31 (8.9)91 (23.5)136 (11.7)46 (8.6)25 (7.9)73 (18.1)0.576
 Site B834 (68.4)421 (74.0)269 (77.3)203 (52.3)806 (69.6)400 (75.0)246 (78.1)228 (56.6)
 Site C152 (12.5)57 (10.0)38 (10.9)67 (17.3)137 (11.8)49 (9.2)31 (9.8)67 (16.6)
 Site D73 (6.0)39 (6.9)10 (2.9)27 (7.0)79 (6.8)38 (7.1)13 (4.1)35 (8.7)
Female sex, n (%)623 (51.1)274 (48.2)189 (54.3)203 (52.3)615 (53.1)263 (49.3)184 (58.4)216 (53.6)0.319
Race, n (%)
 Asian171 (14.0)88 (15.5)62 (17.8)35 (9.0)183 (15.8)89 (16.7)56 (17.8)48 (11.9)0.422
 Black150 (12.3)64 (11.2)50 (14.4)47 (12.1)140 (12.1)66 (12.4)44 (14.0)51 (12.7)
 Other/unknown85 (7.0)46 (8.1)25 (7.2)25 (6.4)66 (5.7)33 (6.2)18 (5.7)21 (5.2)
 White814 (66.7)371 (65.2)211 (60.6)281 (72.4)769 (66.4)345 (64.7)197 (62.5)283 (70.2)
 Hispanic
  No358 (29.3)134 (23.6)77 (22.1)171 (44.1)329 (28.4)125 (23.5)61 (19.4)165 (40.9)0.825
  Unknown717 (58.8)356 (62.6)231 (66.4)183 (47.2)695 (60.0)333 (62.5)213 (67.6)208 (51.6)
  Yes145 (11.9)79 (13.9)40 (11.5)34 (8.8)134 (11.6)75 (14.1)41 (13.0)30 (7.4)
Age at new prescription  (years), n (%)
 18–3959 (4.8)36 (6.3)19 (5.5)6 (1.5)59 (5.1)34 (6.4)18 (5.7)15 (3.7)0.553
 40–64653 (53.5)341 (59.9)199 (57.2)171 (44.1)594 (51.3)316 (59.3)179 (56.8)159 (39.5)
 ≥65508 (41.6)192 (33.7)130 (37.4)211 (54.4)505 (43.6)183 (34.3)118 (37.5)229 (56.8)
Age at new prescription  (years)*
 Mean ± SD61.67 ± 13.0359.10 ± 12.4359.70 ± 12.6366.47 ± 12.4962.04 ± 13.3759.24 ± 12.7959.93 ± 13.4166.23 ± 13.220.390
 Median   (minimum–maximum)62 (19–94)60 (19–94)60.00 (22–91)66 (33–94)63 (19–96)60 (19–96)60 (24–92)67 (28–92)
Drug coverage at new prescription, n (%)*1,020 (83.6)485 (85.2)302 (86.8)298 (76.8)975 (84.2)459 (86.1)271 (86.0)322 (79.9)0.695
Baseline value
 Mean ± SD9.76 ± 1.66% (83 mmol/mol)135.1 ± 31.09155.2 ± 13.51 9.83 ± 1.65% (84 mmol/mol)138.0 ± 30.56 154.6 ± 13.78
 Median  (minimum–maximum)9.3% (8.0–17.9%)
(78 mmol/mol)126.5 mg/dL (100.0–281.0 mg/dL)152.0 mmHg (140.0–214.0 mmHg)9.4% (8.0–15.7%)
(79 mmol/mol)130.0 mg/dL(100.0–274.0 mg/dL)150.0 mmHg (140.0 –220.0 mmHg)
  • Note that a given patient could have elevations in more than one clinical domain.

  • *Time of new prescription for first uncontrolled condition when pooled over all conditions.